Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?
Neurodegenerative disorders such as Parkinson’s (PD) and Huntington’s disease (HD) are characterized by a selective detrimental impact on neurons in a specific brain area. Currently, these diseases have no cures, although some promising trials of therapies that may be able to slow the loss of brain...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-08-01
|
| Series: | Frontiers in Cellular Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fncel.2020.00250/full |
| _version_ | 1828901938018648064 |
|---|---|
| author | Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Unai Perpiña Unai Perpiña Unai Perpiña Unai Perpiña Unai Perpiña Marco Straccia Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Emanuele Cozzi Emanuele Cozzi Anne E. Rosser Anne E. Rosser Anne E. Rosser Josep M. Canals Josep M. Canals Josep M. Canals Josep M. Canals Josep M. Canals |
| author_facet | Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Unai Perpiña Unai Perpiña Unai Perpiña Unai Perpiña Unai Perpiña Marco Straccia Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Emanuele Cozzi Emanuele Cozzi Anne E. Rosser Anne E. Rosser Anne E. Rosser Josep M. Canals Josep M. Canals Josep M. Canals Josep M. Canals Josep M. Canals |
| author_sort | Cristina Salado-Manzano |
| collection | DOAJ |
| description | Neurodegenerative disorders such as Parkinson’s (PD) and Huntington’s disease (HD) are characterized by a selective detrimental impact on neurons in a specific brain area. Currently, these diseases have no cures, although some promising trials of therapies that may be able to slow the loss of brain cells are underway. Cell therapy is distinguished by its potential to replace cells to compensate for those lost to the degenerative process and has shown a great potential to replace degenerated neurons in animal models and in clinical trials in PD and HD patients. Fetal-derived neural progenitor cells, embryonic stem cells or induced pluripotent stem cells are the main cell sources that have been tested in cell therapy approaches. Furthermore, new strategies are emerging, such as the use of adult stem cells, encapsulated cell lines releasing trophic factors or cell-free products, containing an enriched secretome, which have shown beneficial preclinical outcomes. One of the major challenges for these potential new treatments is to overcome the host immune response to the transplanted cells. Immune rejection can cause significant alterations in transplanted and endogenous tissue and requires immunosuppressive drugs that may produce adverse effects. T-, B-lymphocytes and microglia have been recognized as the main effectors in striatal graft rejection. This review aims to summarize the preclinical and clinical studies of cell therapies in PD and HD. In addition, the precautions and strategies to ensure the highest quality of cell grafts, the lowest risk during transplantation and the reduction of a possible immune rejection will be outlined. Altogether, the wide-ranging possibilities of advanced therapy medicinal products (ATMPs) could make therapeutic treatment of these incurable diseases possible in the near future. |
| first_indexed | 2024-12-13T16:08:32Z |
| format | Article |
| id | doaj.art-df6680de93984f5c9159b4eb1ccd0efd |
| institution | Directory Open Access Journal |
| issn | 1662-5102 |
| language | English |
| last_indexed | 2024-12-13T16:08:32Z |
| publishDate | 2020-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular Neuroscience |
| spelling | doaj.art-df6680de93984f5c9159b4eb1ccd0efd2022-12-21T23:39:00ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022020-08-011410.3389/fncel.2020.00250566226Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?Cristina Salado-Manzano0Cristina Salado-Manzano1Cristina Salado-Manzano2Cristina Salado-Manzano3Cristina Salado-Manzano4Unai Perpiña5Unai Perpiña6Unai Perpiña7Unai Perpiña8Unai Perpiña9Marco Straccia10Francisco J. Molina-Ruiz11Francisco J. Molina-Ruiz12Francisco J. Molina-Ruiz13Francisco J. Molina-Ruiz14Francisco J. Molina-Ruiz15Emanuele Cozzi16Emanuele Cozzi17Anne E. Rosser18Anne E. Rosser19Anne E. Rosser20Josep M. Canals21Josep M. Canals22Josep M. Canals23Josep M. Canals24Josep M. Canals25Laboratory of Stem Cells and Regenerative Medicine, Department of Biomedicine, University of Barcelona, Barcelona, SpainProduction and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, Barcelona, SpainInstitute of Neurosciences, University of Barcelona, Barcelona, SpainNetworked Biomedical Research Centre for Neurodegenerative Disorders (CIBERNED), Barcelona, SpainAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, SpainLaboratory of Stem Cells and Regenerative Medicine, Department of Biomedicine, University of Barcelona, Barcelona, SpainProduction and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, Barcelona, SpainInstitute of Neurosciences, University of Barcelona, Barcelona, SpainNetworked Biomedical Research Centre for Neurodegenerative Disorders (CIBERNED), Barcelona, SpainAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, SpainFRESCI by SCIENCE&STRATEGY SL, Barcelona, SpainLaboratory of Stem Cells and Regenerative Medicine, Department of Biomedicine, University of Barcelona, Barcelona, SpainProduction and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, Barcelona, SpainInstitute of Neurosciences, University of Barcelona, Barcelona, SpainNetworked Biomedical Research Centre for Neurodegenerative Disorders (CIBERNED), Barcelona, SpainAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, SpainDepartment of Cardio-Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, ItalyTransplant Immunology Unit, Padua University Hospital, Padua, ItalyDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, United Kingdom0MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom1Brain Repair Group, School of Biosciences, Cardiff University, Cardiff, United KingdomLaboratory of Stem Cells and Regenerative Medicine, Department of Biomedicine, University of Barcelona, Barcelona, SpainProduction and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, Barcelona, SpainInstitute of Neurosciences, University of Barcelona, Barcelona, SpainNetworked Biomedical Research Centre for Neurodegenerative Disorders (CIBERNED), Barcelona, SpainAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, SpainNeurodegenerative disorders such as Parkinson’s (PD) and Huntington’s disease (HD) are characterized by a selective detrimental impact on neurons in a specific brain area. Currently, these diseases have no cures, although some promising trials of therapies that may be able to slow the loss of brain cells are underway. Cell therapy is distinguished by its potential to replace cells to compensate for those lost to the degenerative process and has shown a great potential to replace degenerated neurons in animal models and in clinical trials in PD and HD patients. Fetal-derived neural progenitor cells, embryonic stem cells or induced pluripotent stem cells are the main cell sources that have been tested in cell therapy approaches. Furthermore, new strategies are emerging, such as the use of adult stem cells, encapsulated cell lines releasing trophic factors or cell-free products, containing an enriched secretome, which have shown beneficial preclinical outcomes. One of the major challenges for these potential new treatments is to overcome the host immune response to the transplanted cells. Immune rejection can cause significant alterations in transplanted and endogenous tissue and requires immunosuppressive drugs that may produce adverse effects. T-, B-lymphocytes and microglia have been recognized as the main effectors in striatal graft rejection. This review aims to summarize the preclinical and clinical studies of cell therapies in PD and HD. In addition, the precautions and strategies to ensure the highest quality of cell grafts, the lowest risk during transplantation and the reduction of a possible immune rejection will be outlined. Altogether, the wide-ranging possibilities of advanced therapy medicinal products (ATMPs) could make therapeutic treatment of these incurable diseases possible in the near future.https://www.frontiersin.org/article/10.3389/fncel.2020.00250/fullneurological disordersregenerationtransplantsimmune systemrejection |
| spellingShingle | Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Cristina Salado-Manzano Unai Perpiña Unai Perpiña Unai Perpiña Unai Perpiña Unai Perpiña Marco Straccia Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Francisco J. Molina-Ruiz Emanuele Cozzi Emanuele Cozzi Anne E. Rosser Anne E. Rosser Anne E. Rosser Josep M. Canals Josep M. Canals Josep M. Canals Josep M. Canals Josep M. Canals Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? Frontiers in Cellular Neuroscience neurological disorders regeneration transplants immune system rejection |
| title | Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? |
| title_full | Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? |
| title_fullStr | Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? |
| title_full_unstemmed | Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? |
| title_short | Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? |
| title_sort | is the immunological response a bottleneck for cell therapy in neurodegenerative diseases |
| topic | neurological disorders regeneration transplants immune system rejection |
| url | https://www.frontiersin.org/article/10.3389/fncel.2020.00250/full |
| work_keys_str_mv | AT cristinasaladomanzano istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT cristinasaladomanzano istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT cristinasaladomanzano istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT cristinasaladomanzano istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT cristinasaladomanzano istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT unaiperpina istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT unaiperpina istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT unaiperpina istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT unaiperpina istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT unaiperpina istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT marcostraccia istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT franciscojmolinaruiz istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT franciscojmolinaruiz istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT franciscojmolinaruiz istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT franciscojmolinaruiz istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT franciscojmolinaruiz istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT emanuelecozzi istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT emanuelecozzi istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT anneerosser istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT anneerosser istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT anneerosser istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT josepmcanals istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT josepmcanals istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT josepmcanals istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT josepmcanals istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases AT josepmcanals istheimmunologicalresponseabottleneckforcelltherapyinneurodegenerativediseases |